TEMPO.CO, Washington – American biotech company, Modern, on Thursday, October 29, 2020, said that his party was preparing to launch its Covid-19 vaccine candidate globally.
“We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world,” said Moderna CEO Stephane Bancel in a statement.
In addition to the Phase 3 studies on the Covid-19 vaccine mRNA-1273, which is fully registered, Moderna currently has four courses in Phase 2 studies, according to Bancel.
“Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to improve mRNA-1273,” he said.
On October 22, the mRNA-1273 Phase 3 study completed the registration process for 30,000 participants, with about 37 percent of participants coming from different communities.
An interim analysis of the vaccine’s Phase 1 study, released in The New England Journal of Medicine on July 14, shows that mRNA-1273 is generally well tolerated in all age groups and triggers a rapid and strong immune response to SARS-CoV-2.
ANTARA | XINHUA
– .
